How lurbinectedin works against cancer
Lurbinectedin (brand name Zepzelca) binds to DNA in cancer cells, trapping transcription factors and blocking RNA polymerase II, which halts tumor growth by disrupting gene expression. It targets small cell lung cancer (SCLC) cells with high transcription rates.[1][2]
Approval and key trial results in SCLC
FDA approved lurbinectedin in June 2020 for metastatic SCLC that progressed after platinum-based chemotherapy, based on the phase 2basket trial (PM14-504). In 69 patients, overall response rate (ORR) was 35% (95% CI: 24-48%), with 3% complete responses and 32% partial. Median duration of response was 5.3 months, progression-free survival (PFS) 3.5 months, and overall survival (OS) 9.3 months.[3][4]
Real-world data from a 2023 retrospective study of 69 SCLC patients showed similar ORR of 32%, with median PFS 4.2 months and OS 7.8 months.[5]
Effectiveness in other cancers
Lurbinectedin shows limited activity outside SCLC:
- Mesothelioma: Phase 2 trial (NCT02448625) in 38 patients reported ORR 25%, median PFS 4.1 months, OS 9.7 months.[6]
- BRCA1/2-mutated solid tumors: Phase 2 study (NCT03205346) had ORR 21% in 18 ovarian cancer patients.[7]
- Other trials: Minimal responses in pancreatic, prostate, and head/neck cancers (ORR <10%). Ongoing phase 3 trials test combinations like lurbinectedin/durvalumab in SCLC (ORR 53% in early data).[8]
| Cancer Type | ORR | Median PFS | Median OS | Trial Phase |
|-------------|-----|------------|-----------|-------------|
| Metastatic SCLC (post-chemo) | 35% | 3.5 months | 9.3 months | 2 [3] |
| Pleural mesothelioma | 25% | 4.1 months | 9.7 months | 2 [6] |
| Ovarian (BRCA-mutated) | 21% | Not reported | Not reported | 2 [7] |
How it compares to standard treatments
In SCLC, topotecan (standard second-line) has ORR 24%, PFS 3.3 months, OS 8.4 months from a phase 3 trial—lurbinectedin matches or slightly exceeds these, with better tolerability (less neutropenia).[9][10] No head-to-head trials exist. In combinations, lurbinectedin/irinotecan improved PFS to 5.8 months vs 4.1 months alone.[11]
Common side effects and patient outcomes
Hematologic toxicity is frequent: neutropenia (57%), anemia (46%), thrombocytopenia (28%). Non-hematologic: fatigue (42%), nausea (38%), decreased appetite (28%). Grade 3/4 events led to discontinuation in 8%.[3] Patients report better quality of life than topotecan due to less severe myelosuppression.[12]
Ongoing trials and future use
Phase 3 trials explore frontline SCLC combinations (e.g., with atezolizumab) and maintenance therapy. Early data suggest ORR up to 64% with immunotherapy.[13] No pediatric approvals; adult use dominates.
Sources
[1]: FDA Label - Zepzelca
[2]: Trigo et al., Lancet Oncol 2020
[3]: Trigo et al., Lancet Oncol 2020
[4]: FDA Approval Summary
[5]: Villalona-Calero et al., Lung Cancer 2023
[6]: Scherpereel et al., Lung Cancer 2020
[7]: Ott et al., Gynecol Oncol 2022
[8]: ClinicalTrials.gov - NCT02454972
[9]: O'Brien et al., J Clin Oncol 2015
[10]: FDA Label comparison
[11]: Farago et al., J Thorac Oncol 2021
[12]: Patient-reported outcomes in Trigo trial
[13]: NCT04702737 early data